Novel FDA-approved bexagliflozin drug for treating type 2 diabetes mellitus.
作者信息
Saleem Muhammad M, Zubair Muhammad S, Abbas Soha, Hojeij Moussa
机构信息
Dow Medical College, Dow University of Health Sciences, Karachi, Sindh, Pakistan.
Faculty of Medicine, Lebanese University, Beirut, Lebanon.
出版信息
Ann Med Surg (Lond). 2024 Oct 7;86(11):6399-6403. doi: 10.1097/MS9.0000000000002624. eCollection 2024 Nov.
Abstract
摘要
相似文献
1
Novel FDA-approved bexagliflozin drug for treating type 2 diabetes mellitus.
Ann Med Surg (Lond). 2024 Oct 7;86(11):6399-6403. doi: 10.1097/MS9.0000000000002624. eCollection 2024 Nov.
2
Bexagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, for improvement of glycemia in type 2 diabetes mellitus: a systematic review and meta-analysis.
Expert Opin Pharmacother. 2023 Sep-Dec;24(18):2187-2198. doi: 10.1080/14656566.2023.2269854. Epub 2024 Jan 5.
3
Safety and Effectiveness of Bexagliflozin in Patients With Type 2 Diabetes Mellitus and Stage 3a/3b CKD.
Am J Kidney Dis. 2019 Sep;74(3):328-337. doi: 10.1053/j.ajkd.2019.03.417. Epub 2019 May 14.
4
Efficacy and safety of bexagliflozin compared with dapagliflozin as an adjunct to metformin in Chinese patients with type 2 diabetes mellitus: A 24-week, randomized, double-blind, active-controlled, phase 3 trial.
J Diabetes. 2024 Apr;16(4):e13526. doi: 10.1111/1753-0407.13526.
5
Bexagliflozin as an adjunct to metformin for the treatment of type 2 diabetes in adults: A 24-week, randomized, double-blind, placebo-controlled trial.
Diabetes Obes Metab. 2023 Oct;25(10):2954-2962. doi: 10.1111/dom.15192. Epub 2023 Jul 6.
6
A 96-week, multinational, randomized, double-blind, parallel-group, clinical trial evaluating the safety and effectiveness of bexagliflozin as a monotherapy for adults with type 2 diabetes.
Diabetes Obes Metab. 2019 Nov;21(11):2496-2504. doi: 10.1111/dom.13833. Epub 2019 Aug 8.
7
Efficacy and safety of bexagliflozin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
Diabetes Obes Metab. 2023 Jul;25(7):1794-1802. doi: 10.1111/dom.15051. Epub 2023 Apr 3.
8
A 12-week, randomized, double-blind, placebo-controlled, four-arm dose-finding phase 2 study evaluating bexagliflozin as monotherapy for adults with type 2 diabetes.
Diabetes Obes Metab. 2020 Apr;22(4):566-573. doi: 10.1111/dom.13928. Epub 2019 Dec 11.
9
A 24-week, randomized, double-blind, active-controlled clinical trial comparing bexagliflozin with sitagliptin as an adjunct to metformin for the treatment of type 2 diabetes in adults.
Diabetes Obes Metab. 2019 Oct;21(10):2248-2256. doi: 10.1111/dom.13801. Epub 2019 Jun 30.
10
A 96-week, double-blind, randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adults.
Diabetes Obes Metab. 2023 Jan;25(1):293-301. doi: 10.1111/dom.14875. Epub 2022 Oct 23.
本文引用的文献
1
Efficacy and safety of bexagliflozin compared with dapagliflozin as an adjunct to metformin in Chinese patients with type 2 diabetes mellitus: A 24-week, randomized, double-blind, active-controlled, phase 3 trial.
J Diabetes. 2024 Apr;16(4):e13526. doi: 10.1111/1753-0407.13526.
2
A 96-week, double-blind, randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adults.
Diabetes Obes Metab. 2023 Jan;25(1):293-301. doi: 10.1111/dom.14875. Epub 2022 Oct 23.
3
Effects of novel glucose-lowering drugs on the lipid parameters: A systematic review and meta-analysis.
Ann Med Surg (Lond). 2022 Apr 16;77:103633. doi: 10.1016/j.amsu.2022.103633. eCollection 2022 May.
4
Nitrotyrosine, Nitrated Lipoproteins, and Cardiovascular Dysfunction in Patients with Type 2 Diabetes: What Do We Know and What Remains to Be Explained?
Antioxidants (Basel). 2022 Apr 27;11(5):856. doi: 10.3390/antiox11050856.
5
Evaluation of bexagliflozin in cats with poorly regulated diabetes mellitus.
Can J Vet Res. 2022 Jan;86(1):52-58.
6
IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045.
Diabetes Res Clin Pract. 2022 Jan;183:109119. doi: 10.1016/j.diabres.2021.109119. Epub 2021 Dec 6.
7
Pathogenesis and Clinical Significance of In-Stent Restenosis in Patients with Diabetes.
Int J Environ Res Public Health. 2021 Nov 15;18(22):11970. doi: 10.3390/ijerph182211970.
8
SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications.
Lancet. 2021 Jul 17;398(10296):262-276. doi: 10.1016/S0140-6736(21)00536-5. Epub 2021 Jun 30.
9
A 12-week, randomized, double-blind, placebo-controlled, four-arm dose-finding phase 2 study evaluating bexagliflozin as monotherapy for adults with type 2 diabetes.
Diabetes Obes Metab. 2020 Apr;22(4):566-573. doi: 10.1111/dom.13928. Epub 2019 Dec 11.
10
A 96-week, multinational, randomized, double-blind, parallel-group, clinical trial evaluating the safety and effectiveness of bexagliflozin as a monotherapy for adults with type 2 diabetes.
Diabetes Obes Metab. 2019 Nov;21(11):2496-2504. doi: 10.1111/dom.13833. Epub 2019 Aug 8.
Zotero 插件